
IS-741 is a phospholipase A2 (PLA2) inhibitor under development by Ishihara Sangyo Kaisha and Sumitomo as a potential treatment for pancreatitis 1187575]. Sumitomo is developing the drug in phase II trials for acute pancreatitis 13990261. In an animal model, IS-741 has been shown to prevent pancreatitis-associated lung injury following endotoxemia [337503].
Clinical Trials as Topic, Phospholipases A2, Structure-Activity Relationship, Pancreatitis, Pyridines, Animals, Humans, Enzyme Inhibitors, Phospholipases A
Clinical Trials as Topic, Phospholipases A2, Structure-Activity Relationship, Pancreatitis, Pyridines, Animals, Humans, Enzyme Inhibitors, Phospholipases A
| citations The total number of citations received by all articles of the researcher of interest. | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
